Clinical Trial

A Study of mRNA-1345 Following a Primary Dose of a Licensed Protein Subunit Respiratory Syncytial Virus (RSV) Vaccine in Adult Participants ≥60 Years of Age

Completed Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate safety, tolerability and immunogenicity of mRNA-1345 in participants who have been previously vaccinated with either Arexvy or Abrysvo at least 12 months prior to enrollment, are medically stable and aged ≥60 years.
Protocol Amendment History 1 change
critical Trial completed 2026-05-05
Trial Details
NCT Number NCT07117487
Lead Sponsor ModernaTX, Inc.
Conditions Respiratory Syncytial Virus
Enrollment 507 participants
Start Date 2025-08-05
Primary Completion 2026-03-27 (estimated)
Study Completion 2026-03-27 (estimated)
Updated on ClinicalTrials.gov 2026-05-04